Evidence map›Paper›PMID 41639288›Full record

ArticleAnnals of hematology2026

Maladaptive somatic gene rescue as predisposition to JAK2 molecular abnormalities? Insights from an Israeli family.

Oscar Borsani, Carmelo Gurnari, Daniela Pietra, Elisa Rumi

Abstract readCase Reports
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Oscar BorsaniDepartment of Molecular Medicine, University of Pavia, Viale Golgi 19, Pavia, 27100, Italy.
Carmelo GurnariDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Daniela PietraDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Elisa RumiDepartment of Molecular Medicine, University of Pavia, Viale Golgi 19, Pavia, 27100, Italy. elisarumi@hotmail.com.ORCID http://orcid.org/0000-0002-7572-9504

Funding

Associazione Italiana per la Ricerca sul Cancro IG 2021 ID 25703
6 · The paper itself

Abstract

Eosinophilia associated with PCM1::JAK2 fusion and classic Philadelphia (Ph)-negative myeloproliferative neoplasms (MPN) are both clonal disorders caused by a dysregulation of the JAK2 signaling pathway. The myeloid neoplasm with t(8;9)(p22;p24.1) and PCM1::JAK2 rearrangement is now formally included among the myeloid/lymphoid neoplasms with eosinophilia (M/LN-eo) and tyrosine kinase fusion genes. To date, no data on genetic predisposition to M/LN-eo with PCM1::JAK2 rearrangement are known, while it is well recognized that a subset of classic Ph-negative MPN segregates within families, suggesting a role for germline predisposition in disease etiology. Here we report the first pedigree with a case of classic Ph-negative MPN and a case of M/LN-eo with PCM1::JAK2. Our patient carried two acquired molecular abnormalities involving JAK2 gene (PCM1::JAK2 fusion and JAK2 H531Y) along with a germline mutation (BLM Y736fs*5, variant allele frequency VAF 41.7%), whereas his sister had the canonical JAK2 V617F driver mutation. This particular pedigree could arise the hypothesis of a genetic predisposition to acquire different JAK2 molecular abnormalities as a maladaptive somatic genetic rescue of an underlying germline predisposition, namely the germline BLM Y736fs*5 mutation.

Indexed as

Genetic Predisposition to DiseaseJanus Kinase 2Myeloproliferative DisordersEosinophiliaFemaleGerm-Line MutationHumansMaleMiddle AgedPedigreeJAK2 protein, humanJanus Kinase 2BLMFamilialJAK2MyeloproliferativePredisposition

Identifiers

PMID41639288
PMCPMC12872617

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.